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Abstract 
Background: It is well known that fibrin network binds a large variety of proteins, including inhibitors and activa-
tors of fibrinolysis, which may affect clot properties, such as stability and susceptibility to fibrinolysis. Specific plasma 
clot composition differs between individuals and may change in disease states. However, the plasma clot proteome 
has not yet been in-depth analyzed, mainly due to technical difficulty related to the presence of a highly abundant 
protein—fibrinogen and fibrin that forms a plasma clot.
Methods: The aim of our study was to optimize quantitative proteomic analysis of fibrin clots prepared ex vivo from 
citrated plasma of the peripheral blood drawn from patients with prior venous thromboembolism (VTE). We used a 
multiple enzyme digestion filter aided sample preparation, a multienzyme digestion (MED) FASP method combined 
with LC–MS/MS analysis performed on a Proxeon Easy-nLC System coupled to the Q Exactive HF mass spectrometer. 
We also evaluated the impact of peptide fractionation with pipet-tip strong anion exchange (SAX) method on the 
obtained results.
Results: Our proteomic approach revealed 476 proteins repeatedly identified in the plasma fibrin clots from patients 
with VTE including extracellular vesicle-derived proteins, lipoproteins, fibrinolysis inhibitors, and proteins involved in 
immune responses. The MED FASP method using three different enzymes: LysC, trypsin and chymotrypsin increased 
the number of identified peptides and proteins and their sequence coverage as compared to a single step digestion. 
Peptide fractionation with a pipet-tip strong anion exchange (SAX) protocol increased the depth of proteomic analy-
ses, but also extended the time needed for sample analysis with LC–MS/MS.
Conclusions: The MED FASP method combined with a label-free quantification is an excellent proteomic approach 
for the analysis of fibrin clots prepared ex vivo from citrated plasma of patients with prior VTE.
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Background
Atherothrombotic vascular disease and venous throm-
boembolism (VTE) represent the leading causes of mor-
bidity and mortality in the Western countries [1]. VTE, 
which encompasses deep vein thrombosis (DVT) and 
pulmonary embolism (PE), affects 1–3 patients per 1000 
individuals per year [2, 3]. The pathogenesis of VTE is 
complex and multifactorial [3, 4]. It is the most com-
mon clinical manifestation of hypercoagulable states, 
including inherited (e.g. factor V Leiden, prothrombin 
G20210A mutation, deficiencies of antithrombin, protein 
C and protein S) or acquired (e.g. cancer, antiphospho-
lipid syndrome, pregnancy, older age) conditions, which 
are associated with the higher risk of thrombus forma-
tion [5, 6].
Growing body of evidence indicates that fibrin clot 
properties represent a novel risk factor for arterial 
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and venous thrombosis, especially in younger patients 
with events of unknown etiology. Interestingly, the pro-
thrombotic plasma fibrin clot phenotype in patients 
with venous or arterial thrombosis involves   thin, 
highly-branched fibers, which are resistant to lysis 
[7, 8]. Moreover, it is well known that fibrin network 
binds a large variety of proteins, including fibronectin, 
thrombospondin, von Willebrand factor, α2-antiplasmin 
and interleukin-1 [9, 10]. Of note, binding of fibrinoly-
sis inhibitors and activators to the clot structure may 
affect clot properties, such as stability and susceptibil-
ity to fibrinolysis. This specific plasma clot composition 
differs between individuals and may transiently change 
in disease states. However, the plasma clot proteome, 
particularly with prothrombotic phenotype associ-
ated with either inherited or acquired conditions, has 
not yet been in-depth analyzed, mainly due to techni-
cal difficulty related to the presence of a highly abun-
dant protein—fibrinogen and fibrin that forms a plasma 
clot [11]. Fibrinogen is a plasma glycoprotein, which 
consists of 2 Aα-, 2 Bβ- and 2 γ-chains, and it accounts 
for as much as 75% of all proteins present in the blood 
clot [12]. Therefore, the proteomic analysis of plasma 
clots is challenging and until recently only a few reports 
have described the clot proteome [11, 13, 14]. Talens 
et al. using 2D gel electrophoresis combined with LC–
MS/MS analysis identified 18 different non-covalently 
bound proteins of fibrin clots generated in  vitro from 
plasma of healthy individuals [14]. In turn, Suski et  al. 
applying shotgun proteomics revealed 62 proteins in 
fibrin clots prepared ex  vivo from plasma of patients 
with acute myocardial infarction [13].
The filter aided sample preparation (FASP) and the 
multiple enzyme digestion FASP (MED FASP) are one of 
the most effective proteomic methods for sample prepa-
ration. They are reproducible and have high performance 
with increased depth of proteomic analysis and sequence 
coverage [15–17]. Thus, the aim of our study was to apply 
MED FASP and pipet-tip strong anion exchange (SAX) 
fractionation combined with LC–MS/MS analysis to 
optimize quantitative proteomic analysis of fibrin clots 
prepared ex vivo from citrated plasma of the peripheral 
blood.
Methods
Patients
Citrated plasma was obtained from four ambulatory 
patients with prior VTE episode. The diagnosis of DVT 
of the lower or upper limb required a positive finding of 
color duplex sonography. An iliac/caval DVT was defined 
as abnormal duplex flow patterns typical of thrombosis 
or an intraluminal filling defect on contrast computed 
tomography (CT) or magnetic resonance venography. 
The diagnosis of PE was based on the presence of typi-
cal symptoms and positive results of high resolution spi-
ral CT. The Local Ethical Committee in Krakow approved 
the study (135/KBL/OIL/2013), and participants pro-
vided informed consent in accordance with the Declara-
tion of Helsinki.
Blood samples (9:1 of 3.2% trisodium citrate) were cen-
trifuged at 2560×g for 20  min (centrifuge 3K18 model, 
swing-out rotor no. 11133 (Sigma-Aldrich, Germany) 
at 20 °C within 30 min of collection, immediately frozen, 
and stored in aliquots at − 80 °C until further use.
Plasma clot preparation and lysis
A fibrin clot was prepared using an assay by Pieters 
et al. [18]. Briefly, to 100 μL of citrate plasma was added 
20  mmol/L calcium chloride and 1  U/mL thrombin 
(Merck, USA). This mixture was placed into plastic tubes, 
which were placed into a wet chamber. After 120  min 
of incubation tubes were connected to a reservoir of a 
buffer (0.05  mol/L Tris-HCl, 0.1  mol/L NaCl, pH 7.5), 
which rinsed a fibrin gel for 1 h. The clots were immedi-
ately frozen at −80 °C.
Clots were lysed in a buffer consisting of 0.1  M Tris-
HCl, pH 8.0, 1% SDS and 50  mM DTT at 96  °C for 
10 min.
Protein and peptide determination
Total protein concentration in lysates and the pep-
tide contents in the digests (see below) were assayed 
using a tryptophan fluorescence based WF-assay in a 
microtiter plate format [19]. For measurements, Corn-
ing Costar 96-well black flat bottom polystyrene plates 
(Sigma-Aldrich, Germany) were used.
Multi‑enzyme digestion filter aided sample preparation 
(MED FASP)
Sample aliquots containing 70  µg of total protein were 
processed using the MED FASP method [16] with modi-
fications described recently [15]. Briefly, proteins were 
subsequently cleaved overnight with endoproteinase 
LysC (Wako, Germany), trypsin (Promega, USA) and 
chymotrypsin (Roche, Switzerland) for 18, 3 and 3  h, 
respectively. Peptide containing fractions were collected 
after each digestion step. The enzyme to protein ratio 
was 1:50. Digestions were carried out in 50  mM Tris-
HCl for LysC and trypsin and in 50 mM Tris-HCl, pH 7.8 
and 10 mM  CaCl2 for chymotrypsin. All reactions were 
conducted at 37  °C. Aliquots containing 10  µg of total 
peptides were desalted on  C18-StageTips [20] and con-
centrated to a volume of ~ 5 µL and were stored frozen at 
− 20 °C until mass spectrometric analysis.
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Peptide fractionation by SAX
Peptides were fractionated according to the previously 
described pipet-tip strong anion exchange (SAX) pro-
tocol [21] with minor modifications. Briefly, peptides 
were loaded into tip columns made by stacking six lay-
ers of a3M Empore anion exchange disk (1214-5012, 
Varian, USA) into a 200  μL micropipet tip. For column 
equilibration and elution of fractions, we used Brit-
ton and Robinson universal buffer (BRUB) composed of 
20 mM acetic acid, 20 mM phosphoric acid and 20 mM 
boric acid titrated with NaOH to the desired pH. In the 
experiments where LysC was used, peptides were loaded 
into the pipet-tip column at pH 12 and the three frac-
tions were eluted at pH 6, and 2. Tryptic peptides were 
loaded at pH 5 and eluted at pH 2. The flow-through and 
the fractions were analyzed. The peptides resulting from 
chymotryptic digestion were analyzed directly by liquid 
chromatography LC–MS/MS.
Liquid chromatography: tandem mass spectrometry
Analysis of peptide mixtures was performed using a QEx-
active HF mass spectrometer (Thermo-Fisher Scientific, 
USA). Aliquots containing 5 µg of total peptides were chro-
matographed on a 50 cm column with 75 µm inner diam-
eter packed C18material (Dr. Maisch GmbH, Germany). 
Peptide separation was carried out at 300 nL/min for 90 min 
using a two-step acetonitrile gradient 5–60% over the first 
75 min and 60–95% for the following 15 min. The tempera-
ture of the column oven was 60  °C. The mass spectrom-
eter operated in data-dependent mode with survey scans 
acquired at a resolution of 50 000 at m/z 400 (transient time 
256 ms). Up to the top 15 most abundant isotope patterns 
with charge ≥ +  2 from the survey scan (300–1650  m/z) 
were selected with an isolation window of 1.6 m/z and frag-
mented by Higher Energy Collisional Dissociation   (HCD) 
with normalized collision energies of 25. The maximum 
ion injection times for the survey scan and the MS/MS 
scans were 20 and 60 ms, respectively. The ion target value 
for MS1 and MS2 scan modes was set to 3 × 106 and  105, 
respectively. The dynamic exclusion was 25 s and 10 ppm. 
The mass spectrometry data have been deposited to the 
ProteomeXchange Consortium via the PRIDE partner 
repository [22] with the dataset identifier: PXD006814.
Data analysis
The spectra were searched using MaxQuant software. All 
raw files were searched together in single MaxQuant run 
using separate parameter options for MS-files from anal-
yses of LysC, trypsin and chymotrypsin. A maximum of 
2 missed cleavages was allowed. Carbamidomethylation 
of cysteines was set as a fixed modification. The mini-
mum peptide length was specified to be 7 amino acids. 
The initial maximal mass tolerance in MS mode was set 
to 7  ppm, whereas fragment mass tolerance was set to 
20 ppm for HCD data. The “matching between the runs”-
option was used. The maximum false peptide and protein 
discovery rate was specified as 0.01. Protein abundances 
were calculated using the “Total Protein Approach” 
(TPA) method [23]. The calculations were performed in 
Microsoft Excel. The pathway analysis was performed 
by STRING (version 10) bioinformatic tool (Search Tool 
for the Retrieval of Interacting Genes/Proteins) to reveal 
functional interactions between proteins. Results were 
enriched in GO biological processes and GO cellular 
components with False Discovery Rate (FDR) < 0.05.
Statistical analysis
Data are presented as a mean ±  SEM. The equality of 
variance and the normality of the data were checked. The 
nonparametric Kruskal–Wallis test or one-way analysis 
of variance (ANOVA) with the Tukey’s post hoc test were 
used as appropriate. A value of p < 0.05 was considered 
as statistically significant. All analyses were performed 
using Statistica 10.0 software (StatSoft, Poland).
Results and discussion
Effective protein extraction and digestion to peptides play 
a pivotal role in accurate quantitative proteomic analy-
sis. Recently, proteomic reactor type methods, includ-
ing FASP and MED FASP, have been described. In the 
FASP/MED FASP methods samples are completely dis-
solved in sodium dodecyl sulfate (SDS) and consecutively 
digested with up to three enzymes in an ultrafiltration 
unit [16, 17]. Here, we have performed the MED FASP 
method using three different enzymes: LysC, trypsin and 
chymotrypsin or peptide fractionation by the  SAX pro-
tocol to optimize the quantitative proteomic analysis of 
fibrin clots prepared ex vivo from citrated plasma of the 
peripheral blood drawn from patients with VTE. Plasma 
clots of 4 patients (1 man and 3 women) with a mean age 
of 36 years (aged from 30 to 58 years) were studied. There 
were 2 patients with isolated DVT and 2 with isolated PE. 
Unprovoked VTE occurred in 2 individuals. Mean time 
since the VTE event was 12 months.
Firstly, we have evaluated the efficiency of digestion 
with LysC, trypsin and chymotrypsin. The amount of 
eluted peptides to total protein amount processed was 
expressed as a yield (Fig. 1a). The yield of digestion with 
LysC, trypsin and chymotrypsin was around 50, 20 and 
10%, respectively, which gave in a total 80% yield with 
MED FASP. The consecutive digestion of plasma fibrin 
clots with LysC, trypsin and chymotrypsin resulted in 
the increased number of the identified unique peptides 
(2388 ± 66) as compared to a single (1148 ± 55) (LysC) 
step digestion. Peptide fractionation with SAX protocol 
led to the similar number of identified unique peptides 
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as obtained by MED FASP with three different enzymes 
(2250 ± 99) (Fig. 1b). Moreover, both consecutive diges-
tion with LysC, trypsin and chymotrypsin and SAX 
fractionation provided the largest number of identified 
proteins (420 ± 18 and 476 ± 8, respectively) in compari-
son to a single (LysC) step digestion (243 ± 13) (Fig. 1c). 
Of note, SAX approach led to the similar number of iden-
tified proteins as compared to MED FASP with three 
different enzymes, but it also extended the time needed 
for sample analysis with LC–MS/MS, which is a result 
of the increased number of runs. Consecutive digestion 
with LysC, trypsin and chymotrypsin also resulted in a 
better sequence coverage than a single (LysC) or double 
(LysC  +  trypsin) step digestion and SAX fractionation 
as shown for coagulation factor XIII a, antithrombin-III 
and fibrinogen gamma chain (Fig. 1d). Interestingly, the 
differences in sequence coverage between digestion with 
one, two or three enzymes as well as SAX approach were 
negligible for most abundant proteins such as fibrinogen 
gamma chain (Fig. 1d). Noteworthy, our results are con-
sistent with previous one, which have evaluated the MED 
FASP protocols, and confirm the efficiency of the MED 
FASP method in proteomic sample preparation [15, 16].
Recently, a protein quantification method called 
Total Protein Approach (TPA) has been described [23]. 
TPA is applicable to large scale proteomic studies and 
allows to calculate the protein concentrations without 
any requirements of spike-in standards or biochemical 
determination of the sample size. Protein concentrations 
are directly derived from the MS intensity outputs [24]. 
Here, we used TPA method to calculate the average con-
centration of proteins isolated from plasma fibrin clots 
prepared ex  vivo from patients with VTE (Additional 
file 1: Table 1 and Additional file 2: Table 2). The protein 
concentrations of some commonly encountered proteins 
in human plasma fibrin clots measured by MED FASP 
(LysC  +  Trypsin  +  Chymotrypsin) method combined 
with LC–MS/MS were shown in Table  1. Clearly, the 
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Fig. 1 Efficiency of protein to peptide conversion after digestion with LysC, trypsin and chymotrypsin. The yields were expressed as a ratio of the 
amount of eluted peptides to total protein amount processed (a). The number of unique peptides identified after sequential digestion with LysC 
(L), LysC + trypsin (L + T), LysC + trypsin + chymotrypsin (L + T + CT) or peptide fractionation by pipet-tip strong anion exchange (SAX) protocol 
(b). The number of proteins identified after sequential digestion with L, L + T, L + T + CT or peptide fractionation by SAX (c). Sequence coverage 
obtained after sequential digestion with L, L + T, L + T + CT or peptide fractionation by SAX for three different proteins: fibrinogen gamma chain, 
coagulation factor XIII a and antithrombin-III (d). *p < 0.05 as compared to L, #p < 0.05 as compared to L + T, †p < 0.05 as compared to L + T + CT; 
mean ± SEM; n = 4 per group
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most abundant protein in human plasma clots was fibrin-
ogen. Our results indicate that the concentrations of their 
three chains were almost equal (around 300  nmol/g) 
and were at least 10 times higher than concentrations of 
other abundant proteins, such as alpha-2-antiplasmin or 
alpha-2-macroglobulin (Fig. 2a). In turn, coagulation fac-
tors, e.g. coagulation factor IX, XII or V were present in 
human plasma clots at very low concentrations around 
1–20 pmol/g (Table 1). Moreover, the depth of our prot-
eomic analysis using MED FASP was around six order of 
magnitude, which was illustrated by  log10 of protein con-
centrations shown in Fig. 2b. It indicates that MED FASP 
method combined with a label-free quantification is an 
excellent proteomic approach for the analysis of fibrin 
clots prepared ex vivo from plasma of patients with VTE. 
We also carried out a bioinformatic analysis of human 
plasma fibrin clots from patients with VTE, which were 
measured by MED FASP (LysC  +  Typsin  +  Chymot-
rypsin) method combined with LC–MS/MS. Such an 
analysis revealed many functional interactions between 
proteins, which indicates that the most of identified 
proteins were engaged in common molecular pathways 
(Fig. 3). To identify these pathways we used STRING (ver-
sion 10) bioinformatic tool. Among GO biological pro-
cesses significantly enriched in human plasma clots we 
revealed molecular pathways, which we were expecting 
Table 1 The average concentration of some selected proteins present in human plasma fibrin clots measured by MED 
FASP (LysC + Typsin + Chymotrypsin) method combined with LC–MS/MS and Total Protein Approach (TPA)
Protein IDs Protein names Gene names Average concentration (nmol/g)
P08697 Alpha-2-antiplasmin SERPINF2 39.2436
P01023 Alpha-2-macroglobulin A2M 16.1977
P01008 Antithrombin-III SERPINC1 1.6678
P02749 Beta-2-glycoprotein 1 APOH 0.1782
P00740 Coagulation factor IX F9 0.0040
P12259 Coagulation factor V F5 0.0125
P00451 Coagulation factor VIII F8 0.0005
P00748 Coagulation factor XII F12 0.0135
P00488 Coagulation factor XIII A chain F13A1 13.5540
P05160 Coagulation factor XIII B chain F13B 0.0347
P02671 Fibrinogen alpha chain FGA 303.1711
P02675 Fibrinogen beta chain FGB 377.2742
P02679 Fibrinogen gamma chain FGG 324.3229
P02751 Fibronectin FN1 62.3088
P00747 Plasminogen PLG 2.8753
P00734 Prothrombin F2 2.3480
P04004 Vitronectin VTN 1.3471
P04275 von Willebrand factor VWF 0.2985
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Fig. 2 Concentrations of proteins indentified after sequential digestion with LysC + trypsin + chymotrypsin (L + T + CT) calculated by Total Pro-
tein Approach (TPA) (a).  Log10 of protein concentrations illustrates the depth of proteomic analysis using MED FASP (b)
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to find, responsible for blood coagulation, platelet acti-
vation and degranulation, fibrinolysis, immune system 
process, regulation of blood coagulation or response to 
stress (Table 2). Additionally, we performed GO analysis 
by STRING of cellular components significantly enriched 
in human plasma clots from patients with VTE. Interest-
ingly, we found that a large number of proteins identified 
by MED FASP method combined with LC–MS/MS are 
Fig. 3 Bioinformatic analysis by STRING (version 10) of vesicle-mediated transport (a) and immune system (b) proteins identified with MED FASP 
(LysC + Typsin + Chymotrypsin) method combined with LC–MS/MS reveals functional interactions between proteins. Each node represents a 
protein and each edge represents an association. Stronger associations are represented by thicker lines
Table 2 The selected GO biological processes enriched in human plasma fibrin clots by STRING (version 10) bioinformatic 
tool
Pathway ID Pathway description Observed gene count False discovery rate
GO.0072376 Protein activation cascade 46 4.39E−61
GO.0042060 Wound healing 94 6.01E−53
GO.0007596 Blood coagulation 85 1.47E−52
GO.0009611 Response to wounding 95 1.32E−50
GO.0050878 Regulation of body fluid levels 90 8.85E−50
GO.0030168 Platelet activation 61 9.95E−50
GO.0002576 Platelet degranulation 43 1.88E−48
GO.0065008 Regulation of biological quality 167 1.44E−45
GO.0006950 Response to stress 173 8.05E−42
GO.0006956 Complement activation 30 2.20E−39
GO.0016192 Vesicle-mediated transport 91 1.54E−32
GO.0001775 Cell activation 69 5.21E−32
GO.0006887 Exocytosis 49 1.78E−30
GO.2000257 Regulation of protein activation cascade 20 8.87E−28
GO.0006959 Humoral immune response 33 1.54E−25
GO.0002376 Immune system process 101 1.83E−21
GO.0030193 Regulation of blood coagulation 24 5.05E−20
GO.0030195 Negative regulation of blood coagulation 19 4.06E−19
GO.0042730 Fibrinolysis 14 1.23E−17
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derived from various types of extracellular vesicles (EVs): 
exosomes, microparticles or membrane-bounded vesi-
cles (Table 3). EVs are released to the extracellular envi-
ronment by platelets, and to lesser extent by other cells, 
in particular endothelial cells, monocytes or neutrophils 
and they facilitate intercellular communication in various 
processes, e.g. immune response, inflammation or blood 
coagulation [25]. Importantly, circulating EVs could con-
tribute to increased risk of VTE and arterial thrombosis 
[26, 27]. Indeed, higher levels of EVs have been observed 
in carriers of inherited thrombophilic states [28, 29]. The 
presence of EVs in human plasma fibrin clots derived 
from patients with VTE could confirm its role in the 
pathogenesis of thrombosis.
Conclusion
In this study, we have applied MED FASP and SAX frac-
tionation to optimize quantitative proteomic analysis of 
fibrin clots prepared ex vivo from citrated plasma of the 
peripheral blood drawn from patients with prior VTE. 
Our proteomic approach revealed for the first time 476 
proteins repeatedly identified in the plasma fibrin clots 
from patients with VTE. We observed that MED FASP 
method using three different enzymes: LysC, trypsin and 
chymotrypsin increased the number of identified pep-
tides and proteins as well as their sequence coverage as 
compared to a single step digestion. Peptide fractiona-
tion with SAX protocol increased the depth of proteomic 
analysis, but also extended the time needed for sample 
analysis with LC–MS/MS. We found that the human 
plasma fibrin clots from patients with VTE contain extra-
cellular region proteins and extracellular vesicles-derived 
proteins. Further studies on larger patient groups with 
different types of VTE are needed to better characterize 
protein clot composition using proteomic analysis.
In conclusion, the MED FASP method combined with 
a label-free quantification is an excellent proteomic 
approach for the analysis of fibrin clots prepared ex vivo 
from citrated plasma of patients with prior VTE.
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